- A Phase 3 cancer immunotherapy company, CEL-SCI (NYSE:CVM), enters into an underwriting agreement with Kingswood Capital Markets to purchase 1M shares at a price to the public of $22.62 per share.
- The price represents a 5% discount to the company’s June 8, 2021 closing share price.
- Underwriter's 30-day option to purchase up to 15% of the offering at the public price.
- Closing expected to occur on or about June 11, 2021.
CEL-SCI dips on $22.62M capital raise
Recommended For You
About CVM Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CVM | - | - |
CEL-SCI Corporation |